Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
» ASTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ASTX Guru Trades in Q1 2013

Steven Cohen 18,800 sh (New)
Chuck Royce 12,300 sh (unchged)
Jim Simons 469,025 sh (-5.52%)
Zeke Ashton 370,000 sh (-7.5%)
» More
Q2 2013

ASTX Guru Trades in Q2 2013

Paul Tudor Jones 42,700 sh (New)
Jim Simons 962,071 sh (+105.12%)
Steven Cohen 21,079 sh (+12.12%)
Chuck Royce 12,300 sh (unchged)
Zeke Ashton 370,000 sh (unchged)
» More
Q3 2013

ASTX Guru Trades in Q3 2013

Mario Gabelli 157,573 sh (New)
Chuck Royce Sold Out
Zeke Ashton Sold Out
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Jim Simons 569,470 sh (-40.81%)
» More
Q4 2013

ASTX Guru Trades in Q4 2013

Mario Gabelli Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ASTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2013-12-31 Sold Out 0.01%$8.48 - $8.63 $ 8.50%0
Mario Gabelli 2013-09-30 New Buy0.01%$4.43 - $8.86 $ 8.534%157573
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Astex Pharmaceuticals Inc was incorporated in March 1991 as a California corporation and changed its state of incorporation to Delaware in May 1997. It changed its name from SuperGen, Inc. to Astex Pharmaceuticals, Inc. in September 2011. The Company is a pharmaceutical Company dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology and hematology. It is developing a pipeline of novel medicines for partnership with pharmaceutical companies. In July 2011, it completed the acquisition of Astex Therapeutics Limited ('ATL'), a privately held UK-based biotechnology company with particular expertise in fragment-based drug discovery. ATL discovers and develops novel small molecule therapeutics. Using its fragment-based drug discovery platform, Pyramid, ATL has built a pipeline of molecularly-targeted drugs for large pharmaceutical partners and internal development that are at various stages of clinical, pre-clinical and early discovery development. Its main source of revenue is royalty revenues relating to sales of Dacogen (decitabine) for Injection, and it received additional revenue from various partnered programs as these programs reach predetermined developmental milestones. Its current primary developmental efforts revolve around the products progressing out of its small-molecule drug discovery programs. Its two internal programs are SGI-110, a novel second generation hypomethylating agent, and AT13387, a novel Hsp90 inhibitor. Its competitors include ArQule, Inc., Array BioPharma, Crystal Genomics, Exelixis, Infinity Pharmaceuticals, Daiichi Sankyo Group, Vertex Pharmaceuticals, Sanofi, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly & Co., GSK, Novartis AG, Pfizer, Synta Pharmaceuticals, and others. The Company is subject to FDA laws and regulations and regulation by other agencies under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential future federal, state or local laws and regulations.
» More Articles for ASTX

Headlines

Articles On GuruFocus.com
Recommended by fool. Sep 16 2012 

More From Other Websites
Astex Pharmaceuticals Presents Final Results of Phase 2 Study of SGI-110 in Treatment Naïve Elderly... Jun 16 2014
ASTEX PHARMACEUTICALS, INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Oct 11 2013
Otsuka Pharmaceutical Completes Acquisition of Astex Pharmaceuticals Oct 11 2013
Sarissa Capital Highlights Advancement Of Astex Pipeline Compound Oct 09 2013
Sarissa Capital Urges All Shareholders Of Astex Pharmaceuticals To Not Tender Their Shares At... Oct 08 2013
US STOCKS-Futures fall on uncertainty over when impasse will end Oct 03 2013
Is This the Top for Astex Pharmaceuticals, Inc. (ASTX) Oct 03 2013
Astex Pharma shareholder opposes $886 mln bid by Otsuka Oct 02 2013
Astex Shareholder Sarissa Says It Won’t Tender Shares Oct 02 2013
Hedge fund Sarissa opposes Astex sale to Otsuka Oct 02 2013
Sarissa Capital Issues Open Letter Regarding Astex Pharmaceuticals Oct 02 2013
Top Biotech Stock Picks for Q4 2013: An Interview with the Senior Analyst at Oppenheimer & Company Sep 13 2013
Wall Street Transcript Interview with James S.J. Manuso, the Chairman and CEO of Astex... Sep 13 2013
Astex Sued by Shareholder Over $886 Million Otsuka Bid Sep 13 2013
Sarissa’s Denner Targets Astex Amid Ire Over Otsuka Deal Sep 11 2013
Astex Pharmaceuticals, Inc. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into... Sep 09 2013
Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Astex Pharmaceuticals, Inc.... Sep 09 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide